Kerstin B. Menander, M.D., Ph.D.

Kerstin Menander, M.D., Ph.D. has been Peregrine’s Head of Medical Oncology since March 2011. She supports the planning and execution of Peregrine’s numerous clinical trials for oncology indications. Dr. Menander has 30 years of experience in drug development, having held senior positions in Abbott Laboratories, Syntex Laboratories, Introgen Therapeutics, Collagen Corporation, and Cell Pathways. At these companies, she led the clinical and regulatory strategy and development of drugs, biologics, and devices. She has led the international management of various clinical trials, which have supported 15 approvals for various indications in the U.S. and Europe including Lupron^®, the leading therapy for the treatment of prostate cancer. Her regulatory experience includes leading the successful development of several INDs, IDEs, NDAs, BLAs (also accelerated), PMAs and conditional and regular MMAs. Dr. Menander earned her medical degree and Ph.D. in Histology from the University of Lund in Sweden.